<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2026-062</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-10093</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭНДОКРИНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ENDOCRINOLOGY</subject></subj-group></article-categories><title-group><article-title>Новые данные по постковидному синдрому у пациентов с сахарным диабетом 2-го типа</article-title><trans-title-group xml:lang="en"><trans-title>Emerging evidence on post-COVID syndrome in patients with type 2 diabetes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7080-8713</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суханов</surname><given-names>C. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhanov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суханов Сергей Александрович, ассистент кафедры терапии и общей врачебной практики</p><p>603005, Нижний Новгород, площадь Минина и Пожарского, д. 10/1</p></bio><bio xml:lang="en"><p>Sergey A. Sukhanov, Assistent of the Department of Therapy and General Medical Practice</p><p>0/1, Minin and Pozharsky Square, Nizhny Novgorod, 60395</p></bio><email xlink:type="simple">sukhanov.aleck@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1830-3600</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Занозина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zanozina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Занозина Ольга Владимировна, д.м.н., доцент, профессор кафедры терапии и общей врачебной практики, Приволжский исследовательский медицинский университет; заведующая эндокринологическим отделением, Нижегородская областная клиническая больница имени Н.А. Семашко</p><p>603005, Нижний Новгород, площадь Минина и Пожарского, д. 10/1,</p><p>603126, Нижний Новгород, ул. Родионова, д. 190</p></bio><bio xml:lang="en"><p>Olga V. Zanozina, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Therapy and General Medical Practice, Privolzhsky Research Medical University; Head of the Endocrinology Department, Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko</p><p>10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950,</p><p>190, Rodionov St., Nizhny Novgorod, 603126</p></bio><email xlink:type="simple">zwx2@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сорокина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sorokina</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сорокина Юлия Андреевна, к.б.н., доцент кафедры общей и клинической фармакологии</p><p>603005, Нижний Новгород, площадь Минина и Пожарского, д. 10/1</p></bio><bio xml:lang="en"><p>Yulia A. Sorokina, Cand. Sci. (Biol.), Associate Professor of the Department of General and Clinical Pharmacology</p><p>0/1, Minin and Pozharsky Square, Nizhny Novgorod, 60395</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лагонская</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Lagonskaya</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лагонская Вероника Николаевна, к.б.н., заведующая отделением клинико-лабораторной диагностики</p><p>603126, Нижний Новгород, ул. Родионова, д. 190</p></bio><bio xml:lang="en"><p>Veronika N. Lagonskaya, Cand. Sci. (Biol.), Head of the Department of Clinical Laboratory Diagnostics</p><p>190, Rodionov St., Nizhny Novgorod, 603126</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кобалава</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kobalava</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кобалава Мери Вепхиаевна, врач-биолог отделения клинико-лабораторной диагностики</p><p>603126, Нижний Новгород, ул. Родионова, д. 190</p></bio><bio xml:lang="en"><p>Meri V. Kobalava, Biologist, Department of Clinical Laboratory Diagnostics</p><p>190, Rodionov St., Nizhny Novgorod, 603126</p></bio><email xlink:type="simple">mery.mery@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Приволжский исследовательский медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Приволжский исследовательский медицинский университет; &#13;
Нижегородская областная клиническая больница имени Н.А. Семашко</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University; &#13;
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Нижегородская областная клиническая больница имени Н.А. Семашко</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>31</day><month>05</month><year>2026</year></pub-date><volume>20</volume><issue>5</issue><fpage>174</fpage><lpage>182</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Суханов C.А., Занозина О.В., Сорокина Ю.А., Лагонская В.Н., Кобалава М.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Суханов C.А., Занозина О.В., Сорокина Ю.А., Лагонская В.Н., Кобалава М.В.</copyright-holder><copyright-holder xml:lang="en">Sukhanov S.A., Zanozina O.V., Sorokina Y.A., Lagonskaya V.N., Kobalava M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/10093">https://www.med-sovet.pro/jour/article/view/10093</self-uri><abstract><p>Пандемия новой коронавирусной инфекции, затронувшая мир, прошла, но проблемы сохранились до сих пор. Долгосрочные последствия COVID-19 остаются недостаточно изученными в настоящее время. Термин «постковидный синдром» (ПКС) в настоящее время имеет временную составляющую, клинико-лабораторную составляющую, определены некоторые биомолекулярные маркеры, факторы риска развития данного осложнения после перенесенной коронавирусной инфекции, уточняется генетическая составляющая постковидного синдрома. Вместе с тем относительно постковидного синдрома у пациентов с сахарным диабетом 2-го типа (СД2) данные разноречивые: например, данные по распространенности постковидных нарушений очень отличаются даже в пределах одной страны. В среднем в Европе частота ПКС у пациентов с СД2 – 66,8%, причем максимальная частота – в возрасте 50 лет. Появляются новые биомаркеры постковидного синдрома у пациентов с СД2, разрабатываются прогностические критерии его развития у данной категории пациентов. Показано, что у пациентов с СД2 и постковидным синдромом длина теломер была достоверно меньше, чем у лиц без постковидных нарушений. Критерием данного синдрома могут служить высокие уровни подоцит-специфических белков и нейтрофильной эластазы. Нами оценена значимость некоторых лейкоцитарных индексов в диагностике и мониторировании последствий перенесенной новой коронавирусной инфекции у пациентов с СД2. Однако остается еще много нерешенных вопросов, в частности, есть ли генетическая предрасположенность к развитию хронического ковида у пациентов с сахарным диабетом. Ранее нами был проведен аналитический обзор по наличию ПКС у пациентов с СД2. Целью настоящей публикации явилось желание обобщить появившиеся в литературе новые данные по основным пунктам, изложенным ранее, и представить собственные результаты.</p></abstract><trans-abstract xml:lang="en"><p>The novel coronavirus pandemic that ravaged the world has passed, but challenges remain. The long-term consequences of COVID-19 are remain poorly understood. The term “post-COVID syndrome” currently has a temporal component, a clinical and laboratory component, some biomolecular markers have been identified, risk factors for the development of this complication after a coronavirus infection have been determined, and the genetic component of post-COVID syndrome is being clarified. However, regarding post-COVID syndrome in patients with type 2 diabetes, the data are conflicting. Data on the prevalence of post-COVID disorders vary widely, even within a single country. On average, in Europe, the frequency of PCOS in patients with type 2 diabetes is 66.8%, with the maximum frequency being at the age of 50 years. New biomarkers of post-COVID syndrome in patients with type 2 diabetes are emerging, and prognostic criteria for its development in this category of patients are being developed. It was shown that the telomere length was significantly shorter in patients with type 2 diabetes mellitus and post-COVID syndrome than in individuals without post-COVID disorders. High levels of podocyte-specific proteins and neutrophil elastase can serve as criteria for this syndrome. We assessed the significance of some leukocyte indices in the diagnosis and monitoring of the consequences of a new coronavirus infection in patients with type 2 diabetes. However, many unanswered questions remain, in particular, whether there is a genetic predisposition to the development of chronic COVID-19 in patients with diabetes. We previously conducted an analytical review of the presence of PCS in patients with type 2 diabetes. The purpose of this publication was to summarize new data in the literature on the main points outlined previously and to present our own results.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лейкоцитарные индексы</kwd><kwd>однонуклеотидный полиморфизм генов</kwd><kwd>сахарный диабет 2-го типа</kwd><kwd>новая коронавирусная инфекция</kwd><kwd>постковидный синдром</kwd></kwd-group><kwd-group xml:lang="en"><kwd>leukocyte indices</kwd><kwd>single nucleotide polymorphism of genes</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>new coronavirus infection</kwd><kwd>post-COVID syndrome</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ким ОТ, Драпкина ОМ, Родионова ЮВ. Публикационная активность исследователей по медицинским специальностям на русском языке во время пандемии COVID-19: «постковидный синдром». Кардиоваскулярная терапия и профилактика. 2022;21(6):3299. https://doi.org/10.15829/1728-8800-2022-3299.</mixed-citation><mixed-citation xml:lang="en">Kim OT, Drapkina OM, Rodionova YuV. Russian-language publication activity of medical researchers in during the COVID-19 pandemic: “post-COVID-19 syndrome”. Cardiovascular Therapy and Prevention. 2022;21(6):3299. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3299.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. https://doi.org/10.1016/j.eclinm.2021.101019.</mixed-citation><mixed-citation xml:lang="en">Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. https://doi.org/10.1016/j.eclinm.2021.101019.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мартынов АИ, Горелов АВ, Малявин АГ (ред.). Особенности течения LongCOVID-инфекции. Терапевтические и реабилитационные мероприятия. 2021. 217 с. Режим доступа: https://www.rnmot.ru/public/uploads/2022/rnmot/МЕТОДИЧЕСКИЕ%20РЕКОМЕНДАЦИИ.pdf.</mixed-citation><mixed-citation xml:lang="en">Мартынов АИ, Горелов АВ, Малявин АГ (ред.). Особенности течения LongCOVID-инфекции. Терапевтические и реабилитационные мероприятия. 2021. 217 с. Режим доступа: https://www.rnmot.ru/public/uploads/2022/rnmot/МЕТОДИЧЕСКИЕ%20РЕКОМЕНДАЦИИ.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Карасева АА, Худякова АД, Гарбузова ЕВ, Рагино ЮИ, Логвиненко ИИ. Степени тяжести постковидного синдрома: систематический обзор. Архивъ внутренней медицины. 2023;13(6):422–435. https://doi.org/10.20514/2226-6704-2023-13-6-422-435.</mixed-citation><mixed-citation xml:lang="en">Karaseva AA, Khudiakova AD, Garbuzova EV, Ragino YuI, Logvinenko II. Severity of Postcovid Syndrome: A Systematic Review. Russian Archive of Internal Medicine. 2023;13(6):422–435. (In Russ.) https://doi.org/10.20514/2226-6704-2023-13-6-422-435.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов ГП, Тарловская ЕИ, Арутюнов АГ, Беленков ЮН, Конради АО, Лопатин ЮМ и др. Клинические особенности постковидного периода. Результаты международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)» (12 месяцев наблюдения). Российский кардиологический журнал. 2023;28(1):5270. https://doi.org/10.15829/1560-4071-2023-5270.</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Tarlovskaya EI, Arutyunov AG, Belenkov YuN, Konradi AO, Lopatin YuM et al. Clinical features of post-COVID period. Results of an International Register “Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)” (12-month follow-up). Russian Journal of Cardiology. 2023;28(1):5270. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5270.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Исаева АВ, Ветлужская МВ, Коробейникова АН, Власова АВ. Клинические фенотипы и особенности течения постковидного синдрома. Профилактическая медицина. 2023;26(9):66–73. https://doi.org/10.17116/profmed20232609166.</mixed-citation><mixed-citation xml:lang="en">Isaeva AV, Vetluzhskaya MV, Korobeynikova AN, Vlasova AV. Clinical phenotypes and features of the post-COVID syndrome course. Profilakticheskaya Meditsina. 2023;26(9):66–73. (In Russ.) https://doi.org/10.17116/profmed20232609166.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Зорина ВВ, Карасева АА, Гарбузова ЕВ, Афанасьева АД, Дума СВ, Суханов АВ и др. Характеристики психоневрологического фенотипа постковидного синдрома. Архивъ внутренней медицины. 2025;15(5):346–357. https://doi.org/10.20514/2226-6704-2025-15-5-346-357.</mixed-citation><mixed-citation xml:lang="en">Zorina VV, Karaseva AA, Garbuzova EV, Afanasyeva AD, Duma SV, Sukhanov AV et al. Characteristics of The Neuropsychiatric Phenotype of Postcovid Syndrome. Russian Archives of Internal Medicine. 2025;15(5):346–357. (In Russ.) https://doi.org/10.20514/2226-6704-2025-15-5-346-357.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Воробьев ПА, Воробьев АП, Краснова ЛС. Постковидный синдром: образ болезни, концепция патогенеза и классификация. Проблемы стандартизации в здравоохранении. 2021;(5-6):3–10. https://doi.org/10.26347/1607-2502202105-06003-010.</mixed-citation><mixed-citation xml:lang="en">Vorobyov PA, Vorobyov AP, Krasnova LS. Post-COVID syndrome: disease character, pathogenesis concept and classification. Health Care Standardization Problems. 2021;(5-6):3–10. (In Russ.) https://doi.org/10.26347/1607-2502202105-06003-010.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gouda P, Zheng S, Peters T, Fudim M, Randhawa VK, Ezekowitz J et al. Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. Curr Heart Fail Rep. 2021;18(5):253–263. https://doi.org/10.1007/s11897-021-00527-w.</mixed-citation><mixed-citation xml:lang="en">Gouda P, Zheng S, Peters T, Fudim M, Randhawa VK, Ezekowitz J et al. Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. Curr Heart Fail Rep. 2021;18(5):253–263. https://doi.org/10.1007/s11897-021-00527-w.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Deutsch AJ, Ahlqvist E, Udler MS. Phenotypic and genetic classification of diabetes. Diabetologia. 2022;65(11):1758–1769. https://doi.org/10.1007/s00125-022-05769-4.</mixed-citation><mixed-citation xml:lang="en">Deutsch AJ, Ahlqvist E, Udler MS. Phenotypic and genetic classification of diabetes. Diabetologia. 2022;65(11):1758–1769. https://doi.org/10.1007/s00125-022-05769-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Schlesinger S, Lang A, Christodoulou N, Linnerz P, Pafili K, Kuss O et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis. Diabetologia. 2023;66(8):1395–1412. https://doi.org/10.1007/s00125-023-05928-1.</mixed-citation><mixed-citation xml:lang="en">Schlesinger S, Lang A, Christodoulou N, Linnerz P, Pafili K, Kuss O et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis. Diabetologia. 2023;66(8):1395–1412. https://doi.org/10.1007/s00125-023-05928-1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Estiri H, Strasser ZH, Brat GA, Semenov YR. Evolving phenotypes of nonhospitalized patients that indicate long COVID. BMC Med. 2021;19(1):249. https://doi.org/10.1186/s12916-021-02115-0.</mixed-citation><mixed-citation xml:lang="en">Estiri H, Strasser ZH, Brat GA, Semenov YR. Evolving phenotypes of nonhospitalized patients that indicate long COVID. BMC Med. 2021;19(1):249. https://doi.org/10.1186/s12916-021-02115-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after COVID-19. Diabetologia. 2022;65(6):949–954. https://doi.org/10.1007/s00125-022-05670-0.</mixed-citation><mixed-citation xml:lang="en">Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after COVID-19. Diabetologia. 2022;65(6):949–954. https://doi.org/10.1007/s00125-022-05670-0.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Салухов ВВ, Арутюнов ГП, Тарловская ЕИ, Батлук ТИ, Башкинов РА, Самусь ИВ и др. Влияние нарушений углеводного обмена на ранние и отдаленные клинические исходы у пациентов с COVID-19 по данным регистров АКТИВ и АКТИВ 2. Проблемы эндокринологии. 2023;69(1):36–49. https://doi.org/10.14341/probl13175.</mixed-citation><mixed-citation xml:lang="en">Salukhov VV, Arutyunov GP, Tarlovskaya EI, Batluk TI, Bashkinov RA, Samus IV et al. The impact of carbohydrate metabolism disorders on the early and long-term clinical outcomes of patients with COVID-19 according to the AKTIV and AKTIV 2 registries. Problemy Endokrinologii. 2023;69(1):36–49. (In Russ.) https://doi.org/10.14341/probl13175.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gavkare AM, Nanaware N, Rayate AS, Mumbre S, Nagoba BS. COVID-19 associated diabetes mellitus: A review. World J Diabetes. 2022;13(9):729–737. https://doi.org/10.4239/wjd.v13.i9.729.</mixed-citation><mixed-citation xml:lang="en">Gavkare AM, Nanaware N, Rayate AS, Mumbre S, Nagoba BS. COVID-19 associated diabetes mellitus: A review. World J Diabetes. 2022;13(9):729–737. https://doi.org/10.4239/wjd.v13.i9.729.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SH, Arora I, Hsia DS, Knowler WC, LeBlanc E, Mylonakis E et al. New-Onset Diabetes After COVID-19. J Clin Endocrinol Metab. 2023;108(11):e1164–e1174. https://doi.org/10.1210/clinem/dgad284.</mixed-citation><mixed-citation xml:lang="en">Kim SH, Arora I, Hsia DS, Knowler WC, LeBlanc E, Mylonakis E et al. New-Onset Diabetes After COVID-19. J Clin Endocrinol Metab. 2023;108(11):e1164–e1174. https://doi.org/10.1210/clinem/dgad284.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cromer SJ, Colling C, Schatoff D, Leary M, Stamou MI, Selen DJ et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complications. 2022;36(4):108145. https://doi.org/10.1016/j.jdiacomp.2022.108145.</mixed-citation><mixed-citation xml:lang="en">Cromer SJ, Colling C, Schatoff D, Leary M, Stamou MI, Selen DJ et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complications. 2022;36(4):108145. https://doi.org/10.1016/j.jdiacomp.2022.108145.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC et al. The incidence of diabetes among 2,777,768 veterans with and without recent SARS-CoV-2 infection. Diabetes Care. 2022;45(4):782–788. https://doi.org/10.2337/dc21-1686.</mixed-citation><mixed-citation xml:lang="en">Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC et al. The incidence of diabetes among 2,777,768 veterans with and without recent SARS-CoV-2 infection. Diabetes Care. 2022;45(4):782–788. https://doi.org/10.2337/dc21-1686.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311–321. https://doi.org/10.1016/S2213-8587(22)00044-4.</mixed-citation><mixed-citation xml:lang="en">Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311–321. https://doi.org/10.1016/S2213-8587(22)00044-4.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wang R, Lin M, Yu S, Xue X, Hu X, Wang Z. Predictors of post-COVID-19 syndrome: a meta-analysis. J Infect Dev Ctries. 2025;19(4):490–497. https://doi.org/10.3855/jidc.18574.</mixed-citation><mixed-citation xml:lang="en">Wang R, Lin M, Yu S, Xue X, Hu X, Wang Z. Predictors of post-COVID-19 syndrome: a meta-analysis. J Infect Dev Ctries. 2025;19(4):490–497. https://doi.org/10.3855/jidc.18574.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Adebisi YA, Alhur AA, Alshahrani NZ, Cañezo VCJr, Cue EG, Lucero-Prisno DE3rd. Pre-pandemic diabetes and risk of long COVID: longitudinal evidence. J Diabetes Metab Disord. 2025;24(2):207. https://doi.org/10.1007/s40200-025-01731-4.</mixed-citation><mixed-citation xml:lang="en">Adebisi YA, Alhur AA, Alshahrani NZ, Cañezo VCJr, Cue EG, Lucero-Prisno DE3rd. Pre-pandemic diabetes and risk of long COVID: longitudinal evidence. J Diabetes Metab Disord. 2025;24(2):207. https://doi.org/10.1007/s40200-025-01731-4.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. https://doi.org/10.1038/s41591-021-01292-y.</mixed-citation><mixed-citation xml:lang="en">Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. https://doi.org/10.1038/s41591-021-01292-y.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Matviichuk A, Yerokhovych V, Zemskov S, Ilkiv Y, Gurianov V, Shaienko Z et al. Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes. Front Endocrinol. 2024;15:1459171. https://doi.org/10.3389/fendo.2024.1459171.</mixed-citation><mixed-citation xml:lang="en">Matviichuk A, Yerokhovych V, Zemskov S, Ilkiv Y, Gurianov V, Shaienko Z et al. Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes. Front Endocrinol. 2024;15:1459171. https://doi.org/10.3389/fendo.2024.1459171.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157–1172. https://doi.org/10.1093/eurheartj/ehac031.</mixed-citation><mixed-citation xml:lang="en">Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157–1172. https://doi.org/10.1093/eurheartj/ehac031.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sk Abd Razak R, Ismail A, Abdul Aziz AF, Suddin LS, Azzeri A, Sha’ari NI. Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):1785. https://doi.org/10.1186/s12889-024-19264-5.</mixed-citation><mixed-citation xml:lang="en">Sk Abd Razak R, Ismail A, Abdul Aziz AF, Suddin LS, Azzeri A, Sha’ari NI. Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):1785. https://doi.org/10.1186/s12889-024-19264-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cox ER, Plotnikoff RC, Gibson PG, Keating SE, Acharya S, Lewthwaite H. Prevalence of Long COVID and the Impact on Diabetes Management and Physical Activity Participation in Adults With Type 2 Diabetes: An Australiawide Cross-sectional Online Survey. Can J Diabetes. 2024;48(8):493–501. https://doi.org/10.1016/j.jcjd.2024.08.004.</mixed-citation><mixed-citation xml:lang="en">Cox ER, Plotnikoff RC, Gibson PG, Keating SE, Acharya S, Lewthwaite H. Prevalence of Long COVID and the Impact on Diabetes Management and Physical Activity Participation in Adults With Type 2 Diabetes: An Australiawide Cross-sectional Online Survey. Can J Diabetes. 2024;48(8):493–501. https://doi.org/10.1016/j.jcjd.2024.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. https://doi.org/10.1136/bmj.n693.</mixed-citation><mixed-citation xml:lang="en">Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. https://doi.org/10.1136/bmj.n693.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Викулова ОК, Железнякова АВ, Серков АА, Исаков МА, Вагапова ГР, Валеева ФВ и др. Комплексный анализ постковидных кардиоренальных осложнений у пациентов с сахарным диабетом 1-го и 2-го типа по данным мобильного лечебно-диагностического центра «Диамобиль». Проблемы эндокринологии. 2024;70(4):65–74. https://doi.org/10.14341/probl13426.</mixed-citation><mixed-citation xml:lang="en">Vikulova OК, Zheleznyakova AV, Serkov AA, Isakov MA, Vagapova GR, Valeeva FV et al. Multiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil). Problemy Endokrinologii. 2024;70(4):65–74. (In Russ.) https://doi.org/10.14341/probl13426.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Cuschieri S, Wilk P. Does Pre-existing Diabetes Correlate with Long COVID-19 in Europe? Evidence from the Analysis of the Survey of Health, Ageing and Retirement in Europe’s Corona Surveys. J Diabetes Res. 2024;2024:7459628. https://doi.org/10.1155/2024/7459628.</mixed-citation><mixed-citation xml:lang="en">Cuschieri S, Wilk P. Does Pre-existing Diabetes Correlate with Long COVID-19 in Europe? Evidence from the Analysis of the Survey of Health, Ageing and Retirement in Europe’s Corona Surveys. J Diabetes Res. 2024;2024:7459628. https://doi.org/10.1155/2024/7459628.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов СА, Сорокина ЮА, Занозина ОВ. Постковидный синдром у больных сахарным диабетом 2-го типа: определение, эпидемиология, патофизиология, биомаркеры и генетические ассоциации. Медицинский совет. 2024;18(6):89–97. https://doi.org/10.21518/ms2024-092.</mixed-citation><mixed-citation xml:lang="en">Sukhanov SA, Sorokina YA, Zanozina OV. Post-COVID syndrome in patients with type 2 diabetes: definition, epidemiology, pathophysiology, biomarkers and genetic associations. Meditsinskiy Sovet. 2024;(6):89–97. (In Russ.) https://doi.org/10.21518/ms2024-092.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Adamiec-Mroczek J, Kluz J, Chwałek S, Rabczyński M, Gostomska-Pampuch K, Lewandowski Ł et al. Development of an enzyme-linked immunosorbent assay (ELISA) for determining neutrophil elastase (NE) – a potential useful marker of multi-organ damage observed in COVID-19 and post-Covid-19 (PCS). Front Mol Biosci. 2025;12:1542898. https://doi.org/10.3389/fmolb.2025.1542898.</mixed-citation><mixed-citation xml:lang="en">Adamiec-Mroczek J, Kluz J, Chwałek S, Rabczyński M, Gostomska-Pampuch K, Lewandowski Ł et al. Development of an enzyme-linked immunosorbent assay (ELISA) for determining neutrophil elastase (NE) – a potential useful marker of multi-organ damage observed in COVID-19 and post-Covid-19 (PCS). Front Mol Biosci. 2025;12:1542898. https://doi.org/10.3389/fmolb.2025.1542898.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Matviichuk A, Krasnienkov D, Yerokhovych V, Ilkiv Y, Korcheva V, Gurbych O et al. Association of leukocyte telomere length and HbA1c with post-COVID-19 syndrome in type 2 diabetes: a cross-sectional pilot study. Front Med. 2025;12:1628156. https://doi.org/10.3389/fmed.2025.1628156.</mixed-citation><mixed-citation xml:lang="en">Matviichuk A, Krasnienkov D, Yerokhovych V, Ilkiv Y, Korcheva V, Gurbych O et al. Association of leukocyte telomere length and HbA1c with post-COVID-19 syndrome in type 2 diabetes: a cross-sectional pilot study. Front Med. 2025;12:1628156. https://doi.org/10.3389/fmed.2025.1628156.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Nandula SR, Brichacek B, Sen S. Podocyte-Specific Protein Expression in Urine Exosome Acts as a Marker for Renal Injury in Post-COVID State. Metab Syndr Relat Disord. 2025;23(4):205–210. https://doi.org/10.1089/met.2024.0199.</mixed-citation><mixed-citation xml:lang="en">Nandula SR, Brichacek B, Sen S. Podocyte-Specific Protein Expression in Urine Exosome Acts as a Marker for Renal Injury in Post-COVID State. Metab Syndr Relat Disord. 2025;23(4):205–210. https://doi.org/10.1089/met.2024.0199.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Müller S, Schultze JL. Systems analysis of human innate immunity in COVID-19. Semin Immunol. 2023;68:101778. https://doi.org/10.1016/j.smim.2023.101778.</mixed-citation><mixed-citation xml:lang="en">Müller S, Schultze JL. Systems analysis of human innate immunity in COVID-19. Semin Immunol. 2023;68:101778. https://doi.org/10.1016/j.smim.2023.101778.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Scott NA, Pearmain L, Knight SB, Brand O, Morgan DJ, Jagger C et al. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID. Eur Respir J. 2023;61(5):2202226. https://doi.org/10.1183/13993003.02226-2022.</mixed-citation><mixed-citation xml:lang="en">Scott NA, Pearmain L, Knight SB, Brand O, Morgan DJ, Jagger C et al. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID. Eur Respir J. 2023;61(5):2202226. https://doi.org/10.1183/13993003.02226-2022.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Nuber-Champier A, Breville G, Voruz P, Jacot de Alcântara I, Lalive PH, Allali G et al. Inflammatory predictors of Post-COVID fatigue. Brain Behav Immun Health. 2025;49:101109. https://doi.org/10.1016/j.bbih.2025.101109.</mixed-citation><mixed-citation xml:lang="en">Nuber-Champier A, Breville G, Voruz P, Jacot de Alcântara I, Lalive PH, Allali G et al. Inflammatory predictors of Post-COVID fatigue. Brain Behav Immun Health. 2025;49:101109. https://doi.org/10.1016/j.bbih.2025.101109.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Yanhui L, Jiangang W, Jianping G, Tao W. Post-COVID-19 syndrome and lowgrade inflammation: exploring gender and occupational inequalities in a retrospective cohort study. Int Health. 2025;17(5):720–726. https://doi.org/10.1093/inthealth/ihaf021.</mixed-citation><mixed-citation xml:lang="en">Yanhui L, Jiangang W, Jianping G, Tao W. Post-COVID-19 syndrome and lowgrade inflammation: exploring gender and occupational inequalities in a retrospective cohort study. Int Health. 2025;17(5):720–726. https://doi.org/10.1093/inthealth/ihaf021.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Danila AI, Cioca F, Gadde ST, Daruvuri SP, Timar R, Hogea E. Prognostic Utility of dNLR, ALRI, APRI, and SII in COVID-19 Patients with Diabetes: A Cross-Sectional Study. Diagnostics. 2024;14(15):1685. https://doi.org/10.3390/diagnostics14151685.</mixed-citation><mixed-citation xml:lang="en">Danila AI, Cioca F, Gadde ST, Daruvuri SP, Timar R, Hogea E. Prognostic Utility of dNLR, ALRI, APRI, and SII in COVID-19 Patients with Diabetes: A Cross-Sectional Study. Diagnostics. 2024;14(15):1685. https://doi.org/10.3390/diagnostics14151685.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов СА, Сорокина ЮА, Занозина ОВ, Мосина АА, Капранова ИД. Значимость некоторых лейкоцитарных индексов у пациентов с сахарным диабетом 2-го типа, перенесших новую коронавирусную инфекцию. Медицинский совет. 2025;19(16):283–290. https://doi.org/10.21518/ms2025-375.</mixed-citation><mixed-citation xml:lang="en">Sukhanov SA, Sorokina YuA, Zanozina OV, Mosinа АА, Kapranova ID. Significance of certain leukocyte indices in patients with type 2 diabetes who have had novel coronavirus infection. Meditsinskiy Sovet. 2025;19(16):283–290. (In Russ.) https://doi.org/10.21518/ms2025-375.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Tao Y, Zhao R, Han J, Li Y. Assessing the causal relationship between COVID-19 and post-COVID-19 syndrome: A Mendelian randomisation study. J Glob Health. 2023;13:06054. https://doi.org/10.7189/jogh.13.06054.</mixed-citation><mixed-citation xml:lang="en">Tao Y, Zhao R, Han J, Li Y. Assessing the causal relationship between COVID-19 and post-COVID-19 syndrome: A Mendelian randomisation study. J Glob Health. 2023;13:06054. https://doi.org/10.7189/jogh.13.06054.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Udler MS. Type 2 Diabetes: Multiple Genes, Multiple Diseases. Curr Diab Rep. 2019;19(8):55. https://doi.org/10.1007/s11892-019-1169-7.</mixed-citation><mixed-citation xml:lang="en">Udler MS. Type 2 Diabetes: Multiple Genes, Multiple Diseases. Curr Diab Rep. 2019;19(8):55. https://doi.org/10.1007/s11892-019-1169-7.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Беляков НА, Трофимова ТН, Рассохин ВВ, Рыбакова МГ, Васильев ВБ. Постковидный синдром – полиморфизм нарушений при новой коронавирусной инфекции. ВИЧ-инфекция и иммуносупрессии. 2021;13(4):7–20. https://doi.org/10.22328/2077-9828-2021-13-4-7-20.</mixed-citation><mixed-citation xml:lang="en">Belyakov NA, Trofimova TN, Rassokhin VV, Rybakova MG, Vasiliev VB. Postcovid syndrome – polymorphism of disorders in a new coronavirus infection. HIV Infection and Immunosuppressive Disorders. 2021;13(4):7–20. (In Russ.) https://doi.org/10.22328/2077-9828-2021-13-4-7-20.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Wu KCH, He Q, Bennett AN, Li J, Chan KHK. Shared genetic mechanism between type 2 diabetes and COVID-19 using pathway-based association analysis. Front Genet. 2022;13:1063519. https://doi.org/10.3389/fgene.2022.1063519.</mixed-citation><mixed-citation xml:lang="en">Wu KCH, He Q, Bennett AN, Li J, Chan KHK. Shared genetic mechanism between type 2 diabetes and COVID-19 using pathway-based association analysis. Front Genet. 2022;13:1063519. https://doi.org/10.3389/fgene.2022.1063519.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Nabi AHMN, Ebihara A, Shekhar HU. Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation. World J Virol. 2023;12(3):151–171. https://doi.org/10.5501/wjv.v12.i3.151.</mixed-citation><mixed-citation xml:lang="en">Nabi AHMN, Ebihara A, Shekhar HU. Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation. World J Virol. 2023;12(3):151–171. https://doi.org/10.5501/wjv.v12.i3.151.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-de-Las-Peñas C, Arendt-Nielsen L, Díaz-Gil G, Gómez-Esquer F, Gil-Crujera A, Gómez-Sánchez SM et al. Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes. 2022;13(11):1935. https://doi.org/10.3390/genes13111935.</mixed-citation><mixed-citation xml:lang="en">Fernández-de-Las-Peñas C, Arendt-Nielsen L, Díaz-Gil G, Gómez-Esquer F, Gil-Crujera A, Gómez-Sánchez SM et al. Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes. 2022;13(11):1935. https://doi.org/10.3390/genes13111935.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
